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Phospholipid content in the arterial wall is altered by
metabolic disorders such as diabetes and is an important
contributor to the development and progression of atherosclerotic disease (1–3).
The “phospholipidomic code” representing the pattern
of phospholipids in the setting of health and disease is
becoming an area of interest in an effort to identify unique
biochemical signatures that can influence atherosclerotic
disease prevention and treatment in diabetic patients (3–5).
In particular, ether lipids are known to have diverse biological effects on cellular and intracellular functions, and
have an impact on tissue homeostasis and inflammation, as
well as progression of cardiovascular disease (6, 7).
Ubiquitously expressed phosphatidylethanolamine (PE)
accounts for approximately 20% of mammalian phospholipids (8). The majority of PEs are synthesized in the endoplasmic reticulum (ER) by the CDP-ethanolamine enzymatic
pathway (Kennedy pathway) (9, 10). In the majority of mammalian tissue, the final step of PE synthesis is catalyzed by the
essential enzyme, choline-ethanolamine phosphotransferase

Abbreviations: AA, arachidonic acid; aPC, alkyl ether phosphatidylcholine; CEA, carotid endarterectomy; CEPT1, choline-ethanolamine
phosphotransferase 1; Cer, ceramide; cPLA2, cytosolic phospholipase
A2; ER, endoplasmic reticulum; iPLA2, independent phospholipase A2;
MAX, maximally; MIN, minimally; NLS, neutral loss scan; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol;
PI, phosphatidylinositol; PIS, precursor-ion scan; pPE, plasmenylphosphatidylethanolamine; PS, phosphatidylserine.
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Abstract Patients with diabetes are at higher risk of developing carotid artery stenosis and resultant stroke. Arachidonoyl phospholipids affect plaque inflammation and
vulnerability, but whether diabetic patients have unique
carotid artery phospholipidomic profiles is unknown. We
performed a comprehensive paired analysis of phospholipids in extracranial carotid endarterectomy (CEA) plaques
of matched diabetic and nondiabetic patients and analyzed
mass spectrometry-derived profiles of three phospholipids,
plasmenyl-phosphatidylethanolamine (pPE), phosphatidylserine (PS), and phosphatidylinositol (PI), in maximally (MAX)
and minimally (MIN) diseased CEA segments. We also measured levels of arachidonic acid (AA), produced by pPE
hydrolysis, and choline-ethanolamine phosphotransferase
1 (CEPT1), responsible for most pPE de novo biosynthesis.
In paired analysis, MIN CEA segments had higher levels than
MAX segments of pPE (P < 0.001), PS (P < 0.001), and PI
(P < 0.03). MIN diabetic plaques contained higher levels
than MAX diabetic plaques of arachidonoyl pPE38:4 and
pPE38:5 and CEPT1 was upregulated in diabetic versus nondiabetic plaques. AA levels were relatively greater in MIN
versus MAX segments of all CEA segments, and were higher
in diabetic than nondiabetic plaques. Our findings suggest
that arachidonoyl phospholipids are more likely to be abundant in the extracranial carotid artery plaque of diabetic
rather than nondiabetic patients.—Zayed, M. A., F-F. Hsu,
B. W. Patterson, Y. Yan, U. Naim, M. Darwesh, G. De Silva,
C. Yang, and C. F. Semenkovich. Diabetes adversely affects

Supplemental Material can be found at:
http://www.jlr.org/content/suppl/2018/02/24/jlr.M081026.DC1
.html

1 (CEPT1) (11). Ether lipids derived from PE, such as plasmenyl-PE (pPE), are also synthesized by CEPT1 and are
highly concentrated in vascular tissue and inflammatory
cells (6, 7, 12). Although initial reports link pPE and
CEPT1 to vascular tissue inflammation (3, 13, 14), how
they are associated with human arterial plaque biology is
largely unknown.
Diabetic patients are known to have more vulnerable
carotid artery plaques that lead to a higher risk of resultant
ischemic stroke (15). Prior reports show that the content of
specific lipid subgroups is altered in the homogenates of
heterogeneous whole carotid endarterectomy (CEA) plaques
(2, 3, 14), as well as in plaques from other arterial beds
(4, 16, 17). In this study, we build upon these prior observations by providing the first phospholipidomic analysis
between maximally (MAX) and minimally (MIN) diseased
CEA segments in diabetic and nondiabetic subjects with
high-grade carotid artery stenosis.

Human subjects and tissue processing
Forty-nine subjects with >70% stenosis in the extracranial
carotid artery bifurcation participated in this study, which was
approved by the local Human Research Protection Office. Using
an IRB-approved protocol, all subjects provided research consent
to allow collection of intraoperative CEA plaque specimens at
the time of their CEA. In the operating room, CEA plaques were
removed en bloc from the subject’s carotid bifurcation, and
immediately sectioned into MAX (the segment that is at the level
of the carotid bifurcation) and MIN diseased segments (the segment that is at the plaque periphery distal edge in the internal
carotid artery; Fig. 1A). The CEA plaque segments were independently inspected to confirm that MAX diseased segments had
American Heart Association type IV–VIII atherosclerotic plaques,
and MIN diseased segments had American Heart Association
type I–III atherosclerotic plaques (Fig. 1) (18).

CEA protein and lipid extraction
Plaque segments were immersed in cold hypotonic nondetergent-based lysis buffer [1 M NaHCO3, 1 M sucrose, 1.5 M NaN3,
0.1 M PMSF, and Protease Inhibitor Cocktail Set III (Calbiochem,
San Diego, CA)] for 30 min. All specimens were then homogenized with a high-speed rotational power tissue homogenizer
(Glas-Col, Terre Haute, IN). Homogenized samples underwent
centrifugation (4,697 g for 5 minutes), and the supernatants were
collected and standardized relative to protein concentration
using a colorimetric Bradford protein concentration assay (Bio-Rad,
Hercules, CA). Supernatant aliquots were obtained for each sample and a set quantity of homologous nonnaturally occurring
phospholipid internal standard species was added to each aliquot. This internal standard cocktail included 1,2-dimyristoyl-snglycero-3-phosphocholine [phosphatidylcholine (PC) 14:0/14:0],
dimyristoyl-sn-glycero-3-phosphoethanolamine (PE 14:0/14:0),
dimyristoyl-sn-glycero-3-phosphochoserine [phosphatidylserine (PS)
14:0/14:0], dimyristoyl-sn-glycero-3-phosphoglycerol [phosphatidylglycerol (PG) 14:0/14:0], dipalmitoyl-sn-glycero-3-phosphoinositol
[phosphatidylinositol (PI) 16:0/16:0], and N-lauroyl-D-erythrosphingosine [ceramide (Cer) d18:1/12:0]. Samples were mixed
with lipid extraction buffer [2:2 (v/v) chloroform/methanol]
and the organic phase was collected. Extracts were then dried

Electrospray ionization mass spectrometry
Lipid extracts from MAX and MIN diseased samples obtained
from 17 patients (10 diabetic and 7 nondiabetic; supplemental
Table S1) were analyzed by direct injection electrospray ionization mass spectrometry using a Thermo Vantage triple-quadruple
mass spectrometer (San Jose, CA) and an Accela 1250 UPLC system operated via an Xcalibur operating system. From each extract,
10 ul were loop injected into the electrospray ion source. The
mass spectrometer skimmer was set at ground potential; the electrospray needle was set at 3.0 kV for positive-ion and 2.5 kV for
negative-ion mode operation; and the temperature of the heated
capillary was set at 300°C. Argon was used as the collision gas for
linked scan collision-induced dissociation tandem mass spectrometry. Precursor-ion scan (PIS) and neutral loss scan (NLS) were
used to profile PC (PIS of 184) as [M+H]+ ions, and PE (PIS of
196), PI (PIS of 241), PG (PIS of 153), PS (NLS of 87), and Cer
(NLS of 256) as [M-H] ions, under each optimal collision energy
and collision gas pressure. Supplemental Figs. S1 and S2 provide
an example of two sets of linked scan spectra of the phospholipid
families analyzed in MAX and MIN diseased CEA segments from
a single nondiabetic human subject.
Structures for all phospholipids were identified using a multiple-stage linear ion-trap that was operated at a low energy collision-induced dissociation and high-resolution mass spectrometry.
Phospholipid structural assignments were made as previously
described (20–29), and as summarized in supplemental Tables S2–
S10. Supplemental Figs. S3–S8 provide product-ion spectra that
were used to produce structural determinations for each phospholipid group.

Mass spectrometry phospholipid data analysis
The mass spectrometry-derived lipid mass spectrum for each
sample was averaged over time, and the average background spectrum was subtracted from it. The net sample spectrum were
described as a set of signal intensities of the predefined phospholipid species whose isotopologue distribution patterns for m+0
through m+4 natural abundance isotopologues were determined
using a custom algorithm in MATLAB (Mathworks, Inc., Natick,
MA). Absolute lipid concentration quantitation was obtained by
deriving the ratio of the signal intensity of each species against
the known quantity of the homologous nonnaturally occurring
internal standard species added to the lipid extract samples. This
analysis included 50 PC-related species [including 23 PCs (supplemental Table S2), 16 alkyl ether PCs (aPCs; supplemental Table S3),
and 11 SMs (supplemental Table S4)], 25 PS species (supplemental Table S5), 22 PE-related species [including 11 PEs (supplemental Table S6) and 11 pPEs (supplemental Table S7)], 13 PG
species (supplemental Table S8), 16 PI species (supplemental
Table S9), and 7 Cer species (supplemental Table S10).

Western blotting and ELISA
Lysed tissue homogenates from MAX and MIN diseased samples (from the matched 10 diabetic and 7 nondiabetic human
subjects that underwent mass spectrometry lipidomic analysis;
supplemental Table 1) were separated using a gradient-gel SDSPAGE, and transferred to a PVDF membrane for Western blotting
using anti-human CEPT1 antibody (Abcam). Lysed tissue homogenates from an additional 11 subjects (5 diabetic and 6 nondiabetic, age and comorbidity matched; supplemental Table S11)
were similarly blotted for human anti-cytosolic phospholipase A2
(cPLA2) antibody (Abcam, ab198898), anti-calcium-independent
PLA2 (iPLA2) antibody (Abcam, ab103258), and anti-GAPDH
antibody (Cell Signaling, #2118). Bands were quantified by
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under nitrogen and reconstituted in methanol with 0.25%
NH4OH (29%) (19).
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densitometry. Using the same 11 subject samples evaluated for
cPLA2 protein expression, the levels of nonesterified arachidonic
acid (AA) in MAX and MIN diseased segments were evaluated using
a competitive ELISA assay (Aviva Systems Biology, OKEH02583)
according to manufacturer’s instructions.

patients. A two-tailed Student’s t-test was used to evaluate relative
differences in specific protein and mRNA expression in MAX and
MIN diseased CEA segments from diabetic and nondiabetic
patients. For all statistical tests, P < 0.05 was considered statistically significant and was not adjusted for multiple comparisons.

Quantitative real-time PCR

Confocal microscopy and immunohistochemistry
MAX and MIN diseased segments were serially dehydrated in
15% and 30% sucrose solutions. CEA segments were then embedded in OCT and sectioned at 10 m sections. Following fixation
with 4% paraformaldehyde, tissue sections were denatured, permeablized with 1% Triton/PBS solution, and blocked with 1%
BSA, 0.2% milk powder, 0.3% Triton X-100 solution. CEA sections were then stained with Pentachrome, as previously described
(30), or with anti-CEPT1 antibody (1:50; Proteintech, Rosemont,
IL), followed by labeling with Alexa Fluor 594-conjugated secondary
antibody (1:250; Invitrogen, Waltham, MA). Tissue sections were
counterstained with DAPI and with Alexa Fluor 488-conjugated
Griffonia simplicifolia isolectin-1-B4 (1:100; Invitrogen). Representative images of CEPT1-stained CEA tissue sections were obtained
at 60× magnification using a Nikon A1Rsi confocal microscope.
Using a DFC 3000 G Leica Microsystems inverted fluorescent
microscope, 30 random 20× images were obtained of the superficial intima of MAX and MIN diseased specimens of three diabetic and three nondiabetic patients. Quantitative assessments of
CEPT1- and isolectin-1-B4-positive cells in the superficial intima
were performed using Image J software.

Statistics
A nonparametric Mann-Whitney U test was used to evaluate
differences in age, demographics, and medications between diabetic and nondiabetic subjects who provided CEA plaque specimens. Mass spectrometry descriptive analysis was performed to
evaluate heat map relative fold differences in phospholipid mean
absolute quantities. A nonparametric Wilcoxon two-sample test
was used to evaluate differences between phospholipid groups
between MAX and MIN diseased segments, as well as diabetic and
nondiabetic patient groups. Further subgroup analysis was performed using a univariate signed-rank test to evaluate differences
in phospholipid classes between MAX and MIN diseased segments in all patients combined, or selectively among diabetic and
nondiabetic patients. Similarly, a univariate signed-rank test was
used to evaluate differences in specific phospholipid species in all
patients combined, or selectively among diabetic and nondiabetic
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RESULTS
Patient clinical demographics
Biochemical and molecular analysis of MAX and MIN
diseased human CEA plaque segments was performed using
specimens collected from 49 human subjects (21 diabetic
and 28 nondiabetic). Comparative analysis of subject
demographics and medication profiles revealed no difference in age groups, cardiovascular risk factors, or prevalence of symptomatic carotid artery stenosis prior to CEA
(Table 1). As expected, diabetic subjects were more likely
to be clinically obese (BMI >30; P < 0.001) and taking medications such as -blockers, anti-platelets, and insulin (P <
0.05; Table 1). Matched human subjects were used for each
subgroup analysis (supplemental Tables S2–S4).
CEPT1 expression is elevated in diabetic CEA specimens
Our group recently demonstrated that skeletal muscle
CEPT1 affects insulin sensitivity and lipid metabolism in
diet-induced diabetes (31). To determine whether CEPT1
is similarly altered in the carotid arteries of diabetic human
subjects, we evaluated CEA plaques (Fig. 1A, B) of 17 subjects
and observed a 53% increase in CEPT1 protein expression
in diabetic specimens (P < 0.05; Fig. 1C). Immunofluorescent microscopy detected scattered CEPT1 tissue staining
in the intima of MAX and MIN diseased segments (Fig. 1D).
There was more CEPT1 staining in the superficial intima
of MAX and MIN segments of diabetic subjects (Fig. 1E;
P < 0.001), and even more staining in MAX segments
compared with diseased MIN segments. Expression patterns were further confirmed in an additional 23 human
TABLE 1. Demographics of patients in cohort 1

Age
50–60 (%)
61–70 (%)
71–80 (%)
81–90 (%)
Demographics
Gender (n)
BMI 30 (%)
Current Smoker (%)
Hypertension (%)
Hyperlipidemia (%)
CAD (%)
Stroke (%)
Medications
Antiplatelet (%)
Beta-blocker (%)
Statin (%)
Insulin (%)

Nondiabetic

Diabetic

P

18
29
43
11

10
48
33
10

0.42
0.18
0.51
0.94

M28/F8
14
11
79
82
43
32

M21/F8
67
29
95
90
48
29

0.49
a
<0.001
0.11
0.10
0.42
0.75
0.79

100
25
82
0

76
76
81
33

0.02a
<0.001a
0.92
<0.001a

a
Significance with a nonparametric Mann-Whitney U test. CAD,
coronary artery disease.
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Freshly collected MAX and MIN diseased CEA segments from
23 subjects (8 diabetic and 15 nondiabetic, age and comorbidity
matched; supplemental Table S12) were submerged in liquid
nitrogen and crushed into a fine powder using a mortar and pestle.
Crushed samples were then placed in 1 ml TRIZOL (Thermo
Fisher), and RNA was extracted using an RNeasy Mini kit (Qiagen).
Following extraction, RNA concentration and integrity were evaluated using an Agilent 2100 Bioanalyzer RNA Nano kit (Agilent)
with RIN <8. One microgram of RNA per sample was converted
to cDNA using an iScript cDNA Synthesis kit (Bio-Rad). cDNA
concentration was evaluated using NanoDrop (Thermo Fisher
ND-ONE-W) and adjusted to a standard concentration across
all samples. Quantitative PCR was carried out using the SYBR
Green PCR Master Mix (Applied Biosystems) one-step RT-PCR
protocol using cept1 forward (5′-AGG TGG TCC TCCAAT CAC
TG-3′) and reverse (5′-TGG CAA ACG TAT GTT TCT GG-3′)
primers. Amplification was performed using StepOnePlus realtime PCR system (Thermo Fisher) to determine relative changes
in amplification cycle between different MAX and MIX diseased
CEA specimens.
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subjects (7 diabetic and 16 nondiabetic), with higher cept1
mRNA expression in both the MAX and MIN diseased CEA
segments of diabetic subjects (P < 0.001; Fig. 1F).
Content of pPEs and PSs is increased in MIN diseased
CEA segments
The terminal enzyme of the Kennedy pathway is CEPT1,
and it is responsible for the de novo biosynthesis of the
majority of phospholipids in mammalian tissue, including
pPEs (9, 10). Because we observed higher cept1 expression
in CEA plaque of diabetic subjects, we next evaluated the
potential consequences of this on tissue phospholipid content. Paired mass spectrometry analysis of all major phospholipid groups revealed a significant relative increase in
the absolute quantities of pPEs and PSs in MIN segments
of diabetic subjects (Table 2; P = 0.001 and P < 0.001,
respectively). The relative absolute quantity of PIs was only

increased in MIN segments of nondiabetic subjects (P = 0.03),
and pPEs were only increased in the MIN segments of diabetic subjects (Table 2; P = 0.01). No significant differences
were observed in the relative absolute quantities of PC,
aPC, SM, PE, Cer, or PG groups between MAX and MIN
segments of diabetic and nondiabetic subjects (Table 2).
Arachidonoyl pPEs are more abundant in MIN diseased
CEA segments
To determine which specific pPE and PS species were
most notably altered, we performed a phospholipid subgroup heat map analysis in MAX and MIN diseased segments of diabetic versus nondiabetic subjects (Fig. 2A, C).
This revealed a >20% relative change in the absolute quantities of specific pPEs (pPE36:4, pPE38:4, pPE38:5, and
pPE40:7; Fig. 2A) and PSs (PS38:3, PS38:5, PS40:4, PS40:5,
PS40:6, PS48:4, and PS48:6; Fig. 2C). Compared with
Diabetes influences carotid plaque phospholipids
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Fig. 1. CEA plaques from diabetic subjects have higher CEPT1 expression. A: The extracranial common carotid artery (CCA) bifurcation
is prone to atherosclerosis. Within the plaque there are segments of MAX disease at the level of the carotid bifurcation and segments of MIN
disease at the distal edge of the plaque within the lumen of the internal carotid artery (ICA). ECA, external carotid artery. B: Pentachrome
staining of CEA plaque demonstrates that MIN diseased segments retain an intima layer surrounded by a relatively intact internal elastic
lamina and partial media layer. The MAX segment has a grossly abnormal thick intima layer with areas of necrosis, intra-plaque hemorrhage,
non-intact internal elastic lamina layer, and a thinner medial segment. Black, elastic fibers; yellow, collagen fibers; blue, mucin; bright red,
fibrin. C: Quantified Western blot analysis demonstrates higher CEPT1 protein expression in CEA plaques of diabetic subjects (n = 11) compared with nondiabetic (n = 7) subjects. D: Immunofluorescent staining demonstrates more CEPT1-DAPI-positive cells in the superficial
intima of MAX segments. Isolectin staining for ECs and smooth muscles, DAPI staining for nuclei, and ^ indicates vessel lumen. E: Quantitative analysis of CEPT1-positive cells in five random of 20× images demonstrates higher CEPT1 content in MAX and MIN diseased segments
of diabetic subjects, and also higher content in MAX segments of diabetic (n = 8) and nondiabetic (n = 17) subjects. F: Relative expression
of cept1 was higher in diabetic MAX and MIN diseased segments. Error bars = SEM, *P < 0.05 and ***P < 0.001.
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TABLE 2. Paired phospholipid analysis between MAX and MIN diseased CEA segments in matched nondiabetic
and diabetic subjects
All
Lipid Family

PC
aPC
SM
PE
pPE
PI
Cer
PS
PG
a

MAX
(nmol/ug)

MIN
(nmol/ug)

0.63
0.3
1.51
0.23
0.3
0.14
0.06
0.19
0.02

0.75
0.31
1.57
0.24
0.47
0.19
0.05
0.44
0.02

Nondiabetic
P

MAX
(nmol/ug)

MIN
(nmol/ug)

0.24
0.85
0.68
0.64
a
0.001
0.05a
0.49
<0.001a
0.42

0.67
0.33
1.57
0.25
0.3
0.14
0.06
0.17
0.02

0.97
0.44
2.02
0.23
0.42
0.22
0.07
0.38
0.02

Diabetic
P

MAX
(nmol/ug)

MIN
(nmol/ug)

P

0.11
0.3
0.38
0.81
0.11
0.03a
0.94
0.03a
0.3

0.61
0.28
1.46
0.21
0.29
0.14
0.05
0.2
0.02

0.59
0.21
1.26
0.24
0.51
0.17
0.03
0.5
0.02

1
0.28
1
0.43
0.01a
0.56
0.32
<0.01a
0.97

Significance with a univariate signed-rank test.

AA is more abundant in MIN diseased CEA plaque
segments
Atherosclerosis increases group IVA cPLA2 expression
and activation in the artery media (32), which results in
arachidonoyl phospholipid hydrolysis and the release of
AA (33). Increased AA potentiates tissue inflammation
(34) and is argued to contribute to atheroprogression in
the setting of diabetes (35, 36). To evaluate the potential
contributions of this in CEA plaque of diabetic subjects, we
evaluated cPLA2 protein abundance in MAX and MIN
segments. We observed slightly higher cPLA2 in MAX

segments of both diabetic and nondiabetic subjects
(Fig. 3A, B); however, both MAX and MIN segments from
nondiabetic patients contained more cPLA2 (P < 0.05;
Fig. 3B). We observed no difference in group VIA/B iPLA2 in
both MAX and MIN segments, suggesting that phospholipid
reacylation via this enzyme was not as affected (Fig. 3C, D).
Because the content of both arachidonoyl pPEs and
cPLA2 levels in CEA plaque appeared to be altered relative
to disease severity and the presence of diabetes, we next
explored whether AA content was also different between
MIN and MAX diseased CEA segments. Similar to arachidonoyl pPEs, AA content was relatively higher in MIN segments (Fig. 3E), and AA content was notably higher in
the MIN segments of diabetic subjects (57% higher than
MIN segments of nondiabetic subjects).

DISCUSSION
How diabetes can alter the phospholipidome of carotid
artery plaque to affect stroke outcomes is poorly understood and has direct translational relevance. Lipid-lowering
agents are thought to decrease carotid atheroprogression
and decrease the risk of stroke (37, 38). However, despite

Fig. 2. Differential pPE and PS content in MAX and MIN diseased CEA segments of diabetic and nondiabetic subjects. A: Heat map analysis of mass spectrometry lipidomics of MAX and MIN diseased CEA segments from diabetic (n = 10) versus nondiabetic (n = 7) subjects
demonstrates increased (green) and decreased (red) content of specific pPE species. Among pPEs, the highest (>20%) relative differences
were observed in pPE36:4, pPE38:4, and pPE38:5. B: The absolute quantities of these pPE species are higher in MIN segments compared
with MAX segments. C: Heat map analysis of MAX and MIN segments from diabetic versus nondiabetic subjects also demonstrate increased
and decreased content of specific PS species. Among PSs, the highest relative differences were observed in PS40:5, PS40:6, and PS48:6. D:
The absolute quantity of these PS species is also higher in MIN segments. Error bars = SEM,  P = 0.06, *P < 0.05, **P < 0.01, and ***P < 0.001.
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MAX, the MIN segments of diabetic subjects demonstrated
higher amounts of arachidonoyl species, 1-(1Z-octadecenyl)2-arachidonoyl-sn-glycero-3-phosphoethanolamine (pPE38:4;
32% increase; P < 0.001) and 1-(1Z,9Z-octadecedienyl)2-arachidonoyl-sn-glycero-3-phosphoethanolamine (pPE38:5;
30% increase; P < 0.001; Fig. 2B). Similarly, the absolute
quantities of PS40:5, PS40:6, and PS48:6 were also increased
in MIN segments of diabetic subjects (Figs. 2D). The same
arachidonoyl pPE and PS species were also abundant in
MIN diseased segments of CEA plaques from asymptomatic subjects (who had no stroke symptoms prior to CEA;
supplemental Fig. S9).
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Fig. 3. Differential content of cPLA2 and AA in CEA plaque segments of diabetic subjects. A: Representative
Western blot (WB) demonstrates higher cPLA2 abundance in the MAX and MIN diseased CEA segments of
nondiabetic subjects. GAPDH is a loading control between lanes. B: Quantitative Western blot cPLA2 band
intensity, normalized to GAPDH, demonstrated higher cPLA2 in MIN and MAX diseased segments of nondiabetic subjects (n = 5) compared with diabetic subjects (n = 6). C: Representative Western blot demonstrates
no difference in iPLA2 abundance in the MAX and MIN diseased CEA segments of diabetic and nondiabetic
subjects. D: Quantitative Western blot iPLA2 band intensity, normalized to GAPDH, demonstrates no difference in iPLA2 in MIN and MAX diseased segments of diabetic (n = 6) and nondiabetic subjects (n = 5).
E: ELISA analysis of AA content in MAX and MIN diseased CEA segments demonstrates higher AA content
in MIN segments in both diabetic (n = 7) and nondiabetic (n = 5) patients. Error bars = SEM, *P < 0.05 and
***P < 0.001.

more prevalent use of statins and tighter glycemic control,
diabetic patients are still six times more likely to suffer
from a disabling stroke (15), an observation that is difficult
to reconcile with current treatment guidelines for diabetic
patients with progressive asymptomatic carotid artery stenosis (39, 40). To provide novel insights into the complex
relationship between diabetes and tissue phospholipogenesis, we tested the hypothesis that diabetic subjects have
altered CEPT1 plaque expression and phospholipid content in variably diseased (MIN vs. MAX) carotid artery
plaque segments.
Our results confirm that MIN and MAX diseased CEA
segments have different phospholipidomic profiles. To
our knowledge, our group is the first to evaluate the phospholipidomic content and metabolism of variably diseased

CEA segments from matched human subjects. This is
highly informative, because the angle, curvature, and width
across the carotid bifurcation contribute to differential
intimal shear stress leading to heterogeneous plaque
deposition in the carotid intima with areas of variable
hemorrhage, inflammation, and necrosis (41). Prior studies confirm that diabetic subjects are more likely to have
vulnerable CEA plaque features and altered lipid content
(2, 42). However, the majority of these human studies do not
account for the known heterogeneous nature of CEA
plaques, and are limited by the lack of relatively “lessdiseased” specimen controls.
The role of CEPT1 in human plaque biology is currently completely unknown. As the key terminal enzyme
of the Kennedy pathway (9, 43), it is responsible for the
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Fig. 4. CEPT1-derived pPEs contribute to AA production. LDL
particles internalized by vascular macrophages and smooth muscle
cells are oxidized (ox-LDL). The ox-LDL is hydrolyzed in the cellular lysosomes and peroxisomes to generate triglycerides (TGs) and
free fatty acids. Through the Kennedy pathway, free fatty acids are
utilized in the de novo biosynthesis of pPEs. Hydrolysis of pPEs by
cPLA2 leads to production of AA, which may be released into the
extracellular space to alter plaque physiology and progression. pPEs
can also be converted to PSs in the ER via PS synthases.

facilitate pPE production. At the mitochondrial inner membrane, PS decarboxylase (encoded by Pisd gene) can convert PS to PE species with polyunsaturated fatty acids in the
sn-2 position (55). However, recent gene expression analysis
of phospholipid biogenesis enzymes did not find Pisd to be
differentially expressed in arterial tissue of human diabetic
subjects (56). Thus, the contribution of PS decarboxylase in
PE and pPE production in human arterial tissue, particularly in the setting of diabetes, remains unclear at this time.
In eukaryotic cells, cPLA2 leads to the formation of cellular AA pools via a steady state hydrolysis of the sn-2 ester
bond of pPEs (33, 57). Consistent with prior findings (32),
our data demonstrate differential plaque expression of
cPLA2, with higher content in both MIN and MAX diseased
CEA segments of nondiabetic subjects. No difference was
observed in iPLA2 expression, suggesting that it does not
play as critical of a role in plaque disease severity, and is not
influenced by diabetic status. Interestingly, CEPT1 and
cPLA2 demonstrated opposite expression patterns, suggesting possible negative feedback signaling between the two
enzymatic pathways. This is consistent with recent reports
demonstrating that CEPT1 substrates, such as cystidinediphosphocholine and cytidine-diphosphoethanolamine
(58, 59), are potent cPLA2 inhibitors.
We also observed that specific PS species were altered by
diabetic status and that overall there was no significant difference in PCs. This is consistent with prior work that demonstrates no significant relative change in PCs in diabetic
arterial specimens (2). However, other reports demonstrate altered PS membrane content in the setting of
chronic hyperglycemia and diabetes (43, 60, 61). In the setting of diabetes, increased membrane PSs in red blood
cells and endothelial cells are thought to increase cell-cell
adhesion and promote vessel thrombosis (60). PS synthases
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biosynthesis of PCs, PEs, and pPEs. Our findings are the
first to demonstrate that both CEPT1 protein and cept1
mRNA expression are significantly increased in MIN diseased CEA segments of diabetic subjects. We also observed
that MIN diseased CEA segments contained the highest
content of arachidonoyl pPEs (pPE38:4 and pPE38:5). On
the other hand, MAX diseased CEA segments demonstrated both lower CEPT1 expression and lower arachidonoyl pPE plaque content. The observed correlations
between CEPT1 expression and pPE content in MIN and
MAX diseased CEA segments suggests that CEPT1 is an
important mediator of plaque phospholipogenesis. Our
observations are also consistent with recent reports that
relate a complex interplay between intima lipid infiltration
and inflammation (44, 45), which leads to deleterious/
destabilizing effects at the plaque edge that promote plaque
rupture and thrombosis (46, 47).
These findings also add to the growing body of evidence
that diabetes affects CEPT1 expression and its role in phospholipid metabolism (31, 48). In skeletal muscles, dietinduced diabetes increases murine CEPT1 expression,
and weight loss in obese human subjects decreases CEPT1
expression (31). Mice with a skeletal muscle CEPT1 deficiency have increased insulin sensitivity and altered
muscle tissue lipid compartmentalization with diet-induced
obesity. Similarly, CEPT1 knockdown in the liver (where
it is naturally highly expressed) downregulates PPARdependent gene expression, while CEPT1 overexpression
in the liver leads to increased PPAR-induced gene expression (48). Thus, in the setting of diabetes, it is evident that
CEPT1 generates important phospholipid ligands that can
increase tissue phospholipid content and oxidative stress
(49). Although it is yet to be determined to what extent
CEPT1-mediated phospholipogenesis occurs in human
plaque, our data suggests that it is perhaps more active in
the arterial plaque of diabetic subjects.
LDL particles internalized by macrophages and vascular
smooth muscle cells are oxidized and hydrolyzed into triglycerides and free fatty acids (Fig. 4). Through the Kennedy
pathway, free fatty acids are utilized in the de novo biosynthesis of plasmalogen phospholipids like pPEs, which affect
membrane fluidity and fusion. The sn-2 position of pPEs is
usually occupied by a polyunsaturated fatty acid, especially
AA, which can be released by cPLA2 (12). Tissue pPE content is affected by insulin sensitivity and exercise (50, 51),
and is significantly altered in conditions such as Alzheimer’s
disease (52), Down’s syndrome, schizophrenia (53), and
Zellweger syndrome (7, 12). In vascular tissue, this phospholipid class can lead to increased production of advanced
glycated end products and AA metabolites, such as eisosanoids and prostaglandins (36). Collectively, this is thought
to induce endothelial dysfunction and tissue inflammation, which are strong stimuli for atheroprogression (3, 54).
Our data support this model by demonstrating that MIN
diseased segments have a higher content of both pPE and
AA, with relatively higher AA in both MIN and MAX diseased CEA segments of diabetic subjects (Fig. 4).
In addition to the Kennedy pathway, mammalian cells
have an alternative spatially separated pathway that can also
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in the ER can covert PC, PE, and pPE into PS (8, 9, 58, 62).
Although we did not observe a correlation between the
content of pPE and PS in CEA plaque, it is possible that
elevated pPE content also contributed to elevated PS content in MIN diseased CEA plaques (Fig. 4). Consistent with
prior findings (8, 60, 61), elevated PS content in diabetic
CEA plaques is likely an indicator of progressive disease.
In conclusion, our data demonstrate that diabetic subjects with high-grade carotid artery atherosclerosis have
increased CEPT1 expression and pPE content in the MIN
diseased segments of the carotid plaque. In MIN diseased
CEA segments, AA content is also increased relative to
MAX diseased segments. These findings provide the first
evidence that CEPT1 likely plays an important role in
human plaque vulnerability in diabetic subjects. Future investigations targeting CEPT1 and its downstream phospholipid
ligands may provide new opportunities for the treatment of
human atheroprogression in the setting of diabetes.
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